CLOV (Clover Health Investments, Corp. /De) — AI Stock Analysis & Recommendation

Research of September 15, 2026 · Healthcare / Hospital & Medical Service Plans

TradeFlare's AI research teams rate CLOV a HOLD. The latest price is $4.81.

The research plan

• Entry: $4.66
• Time horizon: N/A

N/A

Why

N/A. Catalysts to watch: Clover Health achieved GAAP net income profitability in Q2 2026 with positive forward EPS and raised guidance; Strong and accelerating revenue growth (55.6% YoY) driven by Medicare Advantage membership gains; High retail investor optimism fueled by potential Humana partnership and Clover Assistant's AI potential. Key risks: Extreme Price Volatility & Deep Drawdown Potential (60%+ annualized historical volatility); Regulatory & Litigation Risk: Ongoing CMS dispute directly threatens $120M in revenue; Persistent Profitability Challenges: Despite recent positive cash flow, TTM net and operating losses persist.

What could push CLOV higher

• Clover Health achieved GAAP net income profitability in Q2 2026 with positive forward EPS and raised guidance.
• Strong and accelerating revenue growth (55.6% YoY) driven by Medicare Advantage membership gains.
• High retail investor optimism fueled by potential Humana partnership and Clover Assistant's AI potential.

Key risks for CLOV

• Extreme Price Volatility & Deep Drawdown Potential (60%+ annualized historical volatility).
• Regulatory & Litigation Risk: Ongoing CMS dispute directly threatens $120M in revenue.
• Persistent Profitability Challenges: Despite recent positive cash flow, TTM net and operating losses persist.

What each AI research team found

Fundamental team: Bullish · valuation: undervalued

Clover Health is demonstrating a strong turnaround, marked by a confirmed pivot to profitability, accelerating revenue growth, and a debt-free balance sheet. Its proprietary technology offers a competitive edge in the expanding Medicare Advantage market, and the stock appears undervalued relative to peers. While challenges like low margins and cash flow quality persist, the positive momentum and growth prospects...

• Clover Health has achieved a significant pivot to GAAP net income profitability in Q2 2026, with positive forward EPS and raised management guidance for full-year profitability.
• The company exhibits strong and accelerating revenue growth (55.6% YoY) driven by Medicare Advantage membership gains.
• A robust financial position is maintained with zero total debt, strong liquidity, and positive operating and free cash flow (though some cash flow quality concerns exist).

Technical team: Bullish

CLOV exhibits a strong underlying uptrend, confirmed by price action above key moving averages and significant accumulation volume, suggesting renewed buyer interest. While immediate resistance and overbought short-term momentum indicators suggest caution, a confirmed breakout above $4.71 would likely lead to a continuation of the bullish trend towards the next resistance level. The overall technical picture...

• Price has decisively moved above key moving averages (MA20, MA50) after consolidation, indicating a strong uptrend and is currently testing immediate resistance.
• A significant green volume spike accompanies the recent bullish price action, confirming strong accumulation and renewed buying interest.
• MACD shows a bullish crossover with increasing histogram bars, and RSI is trending upwards in bullish territory, though the Stochastic Oscillator is overbought and signaling a potential short-term pullback.

Sentiment team: Bullish

Overall sentiment for CLOV is bullish, driven by recent profitability, strong Medicare Advantage growth, and positive analyst upgrades. However, this optimism is tempered by significant insider selling, potential regulatory headwinds, and a mixed analyst consensus, suggesting a degree of caution is warranted. The high retail interest and speculation around a Humana partnership contribute to a strong positive...

• Clover Health's Q2 2026 GAAP profitability and strong Medicare Advantage membership growth, coupled with a Deutsche Bank 'Buy' rating, are positive, but tempered by insider selling, sector-wide legislative headwinds, and past negative reports. (Score: 0.25)
• Retail investors are highly optimistic, fueled by speculation of a Humana partnership, the potential of the Clover Assistant AI platform, and recent profitability, despite some profit-taking and concerns about the 'turnaround being priced in.' (Score: 0.9)
• Professional analysts and institutions show predominantly positive sentiment, driven by recent upgrades, increased price targets, Q2 profitability, and strong Medicare Advantage growth, though insider selling and mixed consensus ratings present some...

Risk team: High

CLOV presents a high-risk profile driven by extreme price volatility, significant regulatory challenges including a critical CMS dispute, and persistent profitability issues. While a post-earnings drift signal exists, the substantial downside potential and high market sensitivity warrant a cautious approach and small position sizing.

• Extreme Price Volatility & Deep Drawdown Potential: CLOV exhibits high historical volatility (60%+ annualized) and has experienced a maximum drawdown of over 72% in the last year, indicating substantial downside risk and significant price swings.
• Regulatory & Litigation Risk (CMS Dispute): An ongoing dispute with the Centers for Medicare & Medicaid Services (CMS) directly threatens $120 million in annual quality bonus revenue, which is critical for the company's profitability and growth.
• Persistent Profitability Challenges & Medical Cost Management: Despite recent positive cash flow, the company faces TTM net and operating losses, struggling to consistently manage medical costs and achieve sustained GAAP profitability in a competitive and...

CLOV at a glance

Market value	$2.5B
Revenue growth (year over year)	54.0%
Profit margin	-0.7%
Debt / equity	0.00

Every AI call on CLOV since May 11, 2026, and what happened next (8 calls) →

Research of September 15, 2026 · AI-generated analysis for educational purposes, can be wrong, not financial advice.